Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation, Safety, Tolerability and Pharmacodynamic Biomarker Study of Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) in Recently Diagnosed, Treatment Naïve Subjects With IPF
NCT05954988 is registered in ClinicalTrials.gov with Rein Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation, Safety, Tolerability and Pharmacodynamic Biomarker Study of Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) in Recently Diagnosed, Treatment Naïve Subjects With IPF
- Lead sponsor
- Rein Therapeutics
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- July 6, 2023
- Completion date
- September 25, 2024
- Enrollment
- 24 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.